Preliminary safety results of an ongoing phase I/II clinical study of MGN1601, a tumor vaccine comprising allogeneic, gene-modified, and irradiated tumor cells in combination with an immunomodulator in patients with metastatic renal cell carcinoma (ASET study).
Marina Tschaika
No relevant relationships to disclose
Steffen Weikert
No relevant relationships to disclose
Viktor Gruenwald
No relevant relationships to disclose
Ingo Schmidt-Wolf
No relevant relationships to disclose
Matthias Schroff
No relevant relationships to disclose
Burghardt Wittig
No relevant relationships to disclose
Manuel Schmidt
No relevant relationships to disclose